Active Not RecruitingActive Not Recruiting
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT06398626 · Pfizer
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A MULTI-CENTER, PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS (ENDEAVOUR-UC)
About this study
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice according to the physician and they have not previously taken etrasimod.
All patients will be prescribed etrasimod according to standard of care. Tests and doctor visits will be conducted according to standard of care with the exception of health questionnaires about ulcerative colitis symptoms. These questionnaires will be completed by patients at various timepoints during the study using their mobile phone, tablet, or computer.
The study is 52 weeks with 28 days of safety follow up. The effects of etrasimod will be analyzed for each patient comparing their disease activity prior to the start of etrasimod.
Eligibility criteria
Inclusion Criteria:
1. Age ≥ 18 years and \< 65 years at baseline
2. Patients with confirmed diagnosis of UC who are prescribed etrasimod for moderately to severely active UC
3. Evidence of a personally signed and dated ICD indicating that the patient (or a legally acceptable representative)has been informed of all pertinent aspects of the study
Exclusion Criteria:
1. The presence of clinical findings suggestive of Crohn's disease
2. Severe extensive colitis evidenced by:
1. Physician judgement that the patient is likely to require hospitalization for medical or surgical intervention of any kind for UC (e.g., colectomy) within 12 weeks
2. Current evidence of acute severe UC, fulminant colitis, or toxic megacolon
3. Patients with a stoma or planned UC surgical intervention requiring hospitalization
4. Prior/Concomitant Therapy:
1. Any previous exposure to etrasimod, including participation in the etrasimod clinical program
2. Any co-medication with one of the following conventional therapies: methotrexate or a thiopurine (azathioprine, mercaptopurine, or tioguanine)
3. Any co-medication with one of the following advanced therapies for UC: biologics (a TNF, integrin or cytokine antagonist; JAKi \[filgotinib, tofacitinib, or upadacitinib\]) or with any other S1P receptor modulator
5. Unwillingness or inability to download the web-based tool to complete ePROs on a personal device or not capable of using the web-based tool
6. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family
Study design
Enrollment target: 300 participants
Age groups: adult
Timeline
Starts: 2024-09-17
Estimated completion: 2028-07-01
Last updated: 2026-11-17
Interventions
Drug: Etrasimod
Primary outcomes
- • Proportion of patients with symptomatic remission (Week 12)
Sponsor
Pfizer · industry
Contacts & investigators
InvestigatorPfizer CT.gov Call Center · study_director, Pfizer
All locations (26)
Reddy GI Associates
Mesa, Arizona, United States
Scripps Clinic Torrey Pines
La Jolla, California, United States
United Medical Doctors
Los Alamitos, California, United States
Rocky Mountain Gastroenterology
Littleton, Colorado, United States
Digestive and Liver Center of Florida Kissimmee
Kissimmee, Florida, United States
Gastro Florida
Lutz, Florida, United States
Orlando Health/Digestive Health Institute
Orlando, Florida, United States
Feinberg School of Medicine Northwestern University
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
Suburban Gastroenterology Ltd
Naperville, Illinois, United States
MGG Group Co., Inc., Chevy Chase Clinical Research
Chevy Chase, Maryland, United States
Woodholme Gastroenterology Associates PA
Glen Burnie, Maryland, United States
Virtua Health
Marlton, New Jersey, United States
NYU Langone Health
New York, New York, United States
Lenox Hill Hospital, Northwell Health
New York, New York, United States
University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology
Chapel Hill, North Carolina, United States
OnSite Clinical Solutions, LLC
Charlotte, North Carolina, United States
University of Cincinnati College of Medicine
Cincinnati, Ohio, United States
Gastro Intestinal Research Institute of Northern Ohio, LLC
Westlake, Ohio, United States
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States
Houston Endoscopy & Research Center
Houston, Texas, United States
BI Research Center
Houston, Texas, United States
Brooke Army Medical center
San Antonio, Texas, United States
GI Alliance Research
Southlake, Texas, United States
Washington Gastroenterology
Tacoma, Washington, United States
WVU Medicine J.W Ruby Memorial Hospital
Morgantown, West Virginia, United States